mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

被引:336
作者
Guertin, David A. [1 ,2 ,3 ]
Stevens, Deanna M. [1 ]
Saitoh, Maki [1 ,2 ]
Kinkel, Stephanie [1 ,2 ,3 ]
Crosby, Katherine [4 ]
Sheen, Joon-Ho [1 ,2 ,3 ]
Mullholland, David J. [5 ]
Magnuson, Mark A. [6 ,7 ]
Wu, Hong [5 ]
Sabatini, David M. [1 ,2 ,3 ,8 ]
机构
[1] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA
[2] MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA
[3] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA
[4] Cell Signaling Technol, Danvers, MA 01923 USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA
[6] Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, Nashville, TN 37232 USA
[7] Vanderbilt Univ, Ctr Stem Cell Biol, Sch Med, Nashville, TN 37232 USA
[8] MIT & Harvard, Broad Inst, Cambridge, MA 02141 USA
基金
美国国家卫生研究院;
关键词
RICH AKT-SUBSTRATE; MOTIF PHOSPHORYLATION; TUMOR-DEVELOPMENT; SUPPRESSOR GENE; TOR COMPLEX-2; KINASE-B; RICTOR; RAPAMYCIN; ACTIVATION; AKT/PKB;
D O I
10.1016/j.ccr.2008.12.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
mTOR complex 2 (mTORC2) contains the mammalian target of rapamycin (mTOR) kinase and the Rictor regulatory protein and phosphorylates Akt. Whether this function of mTORC2 is critical for cancer progression is unknown. Here, we show that transformed human prostate epithelial cells lacking PTEN require mTORC2 to form tumors when injected into nude mice. Furthermore, we find that Rictor is a haploinsufficient gene and that deleting one copy protects Pten heterozygous mice from prostate cancer. Finally, we show that the development of prostate cancer caused by Pten deletion specifically in prostate epithelium requires mTORC2, but that for normal prostate epithelial cells, mTORC2 activity is nonessential. The selective requirement for mTORC2 in tumor development suggests that mTORC2 inhibitors may be of substantial clinical utility.
引用
收藏
页码:148 / 159
页数:12
相关论文
共 56 条
[1]  
Abraham RT, 2008, EXPERT OPIN THER TAR, V12, P209, DOI [10.1517/14728222.12.2.209, 10.1517/14728222.12.2.209 ]
[2]   Mechanism of activation of protein kinase B by insulin and IGF-1 [J].
Alessi, DR ;
Andjelkovic, M ;
Caudwell, B ;
Cron, P ;
Morrice, N ;
Cohen, P ;
Hemmings, BA .
EMBO JOURNAL, 1996, 15 (23) :6541-6551
[3]   Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease [J].
Backman, SA ;
Stambolic, V ;
Suzuki, A ;
Haight, J ;
Elia, A ;
Pretorius, J ;
Tsao, MS ;
Shannon, P ;
Bolon, B ;
Ivy, GO ;
Mak, TW .
NATURE GENETICS, 2001, 29 (04) :396-403
[4]   Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN+/- mice [J].
Bayascas, JR ;
Leslie, NR ;
Parsons, R ;
Fleming, S ;
Alessi, DR .
CURRENT BIOLOGY, 2005, 15 (20) :1839-1846
[5]   The two TORCs and Akt [J].
Bhaskar, Prashanth T. ;
Hay, Nissim .
DEVELOPMENTAL CELL, 2007, 12 (04) :487-502
[6]   The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB [J].
Biondi, RM ;
Kieloch, A ;
Currie, RA ;
Deak, M ;
Alessi, DR .
EMBO JOURNAL, 2001, 20 (16) :4380-4390
[7]   The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
[8]   PKBα/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival [J].
Bozulic, Lana ;
Surucu, Banu ;
Hynx, Debby ;
Hemmings, Brian A. .
MOLECULAR CELL, 2008, 30 (02) :203-213
[9]   The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice [J].
Chen, Mei-Ling ;
Xu, Pei-Zhang ;
Peng, Xiao-Ding ;
Chen, William S. ;
Guzman, Grace ;
Yang, Ximing ;
Di Cristofano, Antonio ;
Pandolfi, Pier Paolo ;
Hay, Nissim .
GENES & DEVELOPMENT, 2006, 20 (12) :1569-1574
[10]   Targeting the mTOR signaling network in cancer [J].
Chiang, Gary G. ;
Abraham, Robert T. .
TRENDS IN MOLECULAR MEDICINE, 2007, 13 (10) :433-442